top of page
JOHN MC MURRAY
New Trials in Heart Failure.Where are we at the end of 2020
DAVID BARAN
Cardiogenic Shock
JOHN CLELAND
Iron Deficiency in Heart Failure
MILTON PACKER
Quadruple Therapy as the new standard of care in heart failure with reduced EF
JOSEPH ROGERS
VAD-Destination Therapy or Bridge?
BUD FRAZIER
Ventricular Assist Devices. Present and future
PILAR ESCRIBANO
pre and post capillary pulmonary hypertension. upfront therapy?
STEFAN ANKER
Drug and devices in the treatment of hfpef. new options
ROBERT MENTZ
With arnis and sglt2, how can we manage polipharmacy in hf?
MARCELO DI CARLI
How imaging change the treatment paradigm in cardiomyopathies
Richard krasuski
support in pulmonary hypertension in advanced right heart failure
Carlos morillo
End stage hf patients keep need to keep or remove CRT-d?
Session Presidents 2020
Anique Ducharme, MD
Canadian Society of Cardiology
Marco Mazzanti,MD,FESC
Artificial Intelligence in Cardiology, London, UK
Hector Ventura,MD
Tulane University, New Orleans,USA
Domenico Garielli, MD
President Azzoziazione Italiana de Cardiologia
jayanthi jayawardena,MD
Asia Pacific Heart Network
Sri Lanka
Shelley Zieroth, MD
Past President Canadian Heart Failure Society
Daniel Quesada Chavez,MD
President. Costaricense Asociation of Cardiology
​
Daniel Piñeiro,MD
President elect
Wolrd Heart Federation
Anil Dhall, MD Indian Society Heart Failure
Jose Gonzalez Costello,MD
Sociedad Espñola de Cardiologia
Alberto Lorenzatti,MD
President FAC
Argentina
​
Daniel Sierra Lara Martinez,MD
Mexican Society Of Cardiology, Mexico
​
Miguel Quintana,MD
Past President SPCIC, SPCyCC
Director ICV SMB, Paraguay
​
Adrian D'ovidio,MD
Past President FAC
​
​
Erick Alexanderson, MD, FACC
Director Cardioacademics
Mexico
Omar Santaera, MD
SOLACI
Daniel Piskorz,MD
Past President FAC
​
​
Alvaro Sosa Liprandi,MD
SIAC president elect
Argentina
​
Juan Delgado Jimenez,MD
Sociedad Espñola de Cardiologia
bottom of page